"Lunit is poised to evolve from an Al-based medical imaging company into a pioneering provider of Al healthcare platform"
BioSpectrum Asia|BioSpectrum Asia Oct 2023
Lunit Inc, a pioneering player in South Korea’s medical imaging industry, achieved significant milestones in 2023. The company secured the EU MDR mark and unveiled its cutting-edge 3D breast screening product, known as ‘Lunit INSIGHT DBT.’ Notably, Lunit’s AI technology has been adopted by over 2,000 healthcare institutions worldwide, marking a major accomplishment. Lunit made noteworthy announcements, including their expansion into Saudi Arabia and Europe. Brandon Suh, the CEO of Lunit Inc., shares more about the company’s mission to combat cancer and advance medical image analytics. Edited excerpts;
Ayesha Siddiqui
"Lunit is poised to evolve from an Al-based medical imaging company into a pioneering provider of Al healthcare platform"

Can you provide a brief overview of Lunit’s mission and its core focus in the field of medical AI? 

Lunit is a medical AI company with a mission to conquer cancer. The company’s core focus is on developing AI solutions for precision diagnostics and therapeutics. This includes AI-powered tools for cancer screening and diagnosis, and AI-powered biomarkers that can enable new therapeutic development and then accurately guide patients to specific cancer therapies. By ensuring timely diagnosis and effective treatment for each patient, Lunit aims to increase the chance of survival by detecting early-stage cancers and helps increase immunotherapy efficacy by accurately predicting treatment response.

Lunit has received recognition in international AI competitions, even surpassing tech giants. What do you believe sets Lunit apart from the competition? 

Diese Geschichte stammt aus der BioSpectrum Asia Oct 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der BioSpectrum Asia Oct 2023-Ausgabe von BioSpectrum Asia.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIOSPECTRUM ASIAAlle anzeigen
Prof. Christian Wolfrum to join NTU as Deputy President and Provost
BioSpectrum Asia

Prof. Christian Wolfrum to join NTU as Deputy President and Provost

Nanyang Technological University, Singapore (NTU Singapore) has announced that Professor Christian Wolfrum, an eminent biomedical scientist, will be joining the University as the next Deputy President and Provost.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Japan suggests addition of PVA into drugs for strong antitumour activity
BioSpectrum Asia

Japan suggests addition of PVA into drugs for strong antitumour activity

Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue.

time-read
1 min  |
BioSpectrum Asia Feb 2025
"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"
BioSpectrum Asia

"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"

2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.

time-read
5 Minuten  |
BioSpectrum Asia Feb 2025
BeiGene names Giancarlo Benelli as Head of Europe biz
BioSpectrum Asia

BeiGene names Giancarlo Benelli as Head of Europe biz

BeiGene, a Hong Kong-headquartered oncology company that intends to change its name to BeOne Medicines Ltd., has announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Korea develops innovative injectable adhesive hydrogel for bone regeneration
BioSpectrum Asia

Korea develops innovative injectable adhesive hydrogel for bone regeneration

A research team from South Korea-based Pohang University of Science and Technology or POSTECH's Department of Chemical Engineering and Graduate School of Convergence Science and Technology, along with the Department of Chemical Engineering, has developed an innovative injectable adhesive hydrogel for bone regeneration.

time-read
1 min  |
BioSpectrum Asia Feb 2025
When Clinical Trials Suffer From 'Complicated' Interactions
BioSpectrum Asia

When Clinical Trials Suffer From 'Complicated' Interactions

Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.

time-read
5 Minuten  |
BioSpectrum Asia Feb 2025
Dr Krishna M Ella receives prestigious INSA India fellowship
BioSpectrum Asia

Dr Krishna M Ella receives prestigious INSA India fellowship

Dr Krishna Ella, a distinguished scientist, co-founder and Executive Chairman of Bharat Biotech International, has been recognised with the prestigious India Fellowship of the Indian National Science Academy (INSA) for the year 2025, for his contributions to new knowledge, discoveries, development of new vaccine technologies, noteworthy improvement in existing technologies.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Bruker launches infrared imaging microscope for pharma and life science research
BioSpectrum Asia

Bruker launches infrared imaging microscope for pharma and life science research

US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade laser (QCL) based infrared (IR) imaging microscope.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities
BioSpectrum Asia

Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities

Qiagen has announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analysed from a single biological sample.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
BioSpectrum Asia

Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers

US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.

time-read
1 min  |
BioSpectrum Asia Feb 2025